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Th  e available treatment options for Alzheimer’s disease 
(AD), the most common chronic, progressive (and 
inevitably fatal) dementing neurological disease, have 
been disappointing in both their paucity and eﬀ  ectiveness 
as compared to other areas of medical intervention such 
as cardiovascular disease and oncology. Th  e AD thera-
peutic picture is hopefully on the verge of a major 
positive change, as numerous clinical trials are now 
testing agents speciﬁ  cally designed to target hypothesized 
etiologic agents of AD, as opposed to the current class of 
approved therapies that oﬀ  er only modest and transient 
symptomatic relief. One such hypothesis-driven approach 
is amyloid-beta (Aβ) immunotherapy, which is under 
investigation in over a dozen clinical trials by a multitude 
of diﬀ  erent sponsors, including several late stage phase 3 
studies. Th   e results of these trials are eagerly anticipated 
as the underlying rationale directly tests the Aβ hypo  the-
sis and is supported by extraordinarily compelling 
preclinical data. Both the scientiﬁ  c origin and evolution 
of this approach were intimately interwoven with the 
successful exploitation of human genetic ﬁ  ndings that led 
to the development of transgenic animal models of this 
progressive central nervous system disease.
Over a century ago, Dr Alois Alzheimer described the 
neuropathological brain lesions that, to this day, are 
essential in the post-mortem conﬁ  rmation of AD diag-
nosis, namely amyloid plaques and neuroﬁ  brillary tangles. 
Th   ese lesions are composed primarily of the Aβ peptide 
and microtubule-associated tau protein, respectively, 
leaving the ﬁ  eld to question whether one, both or neither 
of these proteins are causative of AD. Aβ is a peptide 
prone to self-aggregation and ﬁ  bril formation leading to 
formation of extracellular plaques. Th  e identiﬁ  cation of 
genetic mutations - linked to autosomal dominant forms 
of AD in the amyloid precursor protein, from which Aβ is 
derived - not only bolstered the amyloid hypothesis but 
allowed for the generation of transgenic mice that 
recapitu  lated many (but not all) human AD-like patho  lo-
gies, including plaque formation, loss of synapses, neuro-
inﬂ  am  mation, cognitive impairments and neuritic dys-
trophy. A major signiﬁ   cance of these ﬁ   ndings is that 
therapies can now be tested for eﬃ   cacy against amyloid-
related pathologies in a tangible context of disease. After 
many years of using human pathology to determine 
relevancy of animal models to disease, the converse 
challenge emerged: would alterations in pathological 
cascades seen in animal models accurately predict human 
response to therapeutic interventions?
Aβ immunotherapy is a deceptively simple idea; expose 
the AD diseased brain to anti-Aβ antibodies, either by 
‘active’ immunization (injection of an Aβ-containing 
immunogen to stimulate a host response) or ‘passive’ 
immunization (administration of a recombinant mono-
clonal antibody) to stimulate the body’s defenses to 
neutralize and clear Aβ as it would other invasive entities. 
Th  e  ﬁ  rst results with active Aβ immunotherapy [1] were 
remarkable in the extent to which the amyloid-associated 
pathologies could be reduced in a transgenic model. 
Importantly, not just the amyloid plaques were cleared, 
but synapses were preserved, neuritic dystrophy was 
reduced and neuro-inﬂ  ammation subsided. Th  ese  results 
were rapidly replicated and expanded upon in labs around 
the world and now behavioral deﬁ  cits and neuronal loss 
[2] can be included in the list of preclinical in vivo
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validation of their translational accuracy is the purview of 
ongoing late stage clinical trials, but several encouraging 
results have been reported. Th  e ﬁ  rst demonstration of 
treatment-associated plaque reduction in AD brain was 
identiﬁ   ed upon post-mortem evaluation of an actively 
immunized patient [3]. Reduction in neuritic dystrophy 
was also observed, and the presence of activated micro-
glia with internalized Aβ indicated at least one down-
stream cellular mechanism was similarly invoked in both 
human and transgenic mouse brains. In recent subse-
quent studies, the reduction of tau-positive neuropil 
threads (plaque-associated but not somatic tangles) has 
also been reported in actively immunized AD patients 
(James Nicholl, personal communication). Encouragingly, 
passive immunotherapy with bapineuzumab has been 
also shown to reduce amyloid burden, as visualized by 
PET/PiB methodology, in living AD patients [4]. 
Interestingly, the divergence of PiB burdens between 
control and bapineuzumab-treated patients showed a 
similar time course of separation to that of the clinical 
measures in patients who completed (completers) all 
doses in a Phase 2 Bapineuzumab trial [5]. Success in the 
ongoing phase 3 trials of bapineuzumab would not only 
be a tremendous validation of preclinical modeling of a 
progressive neurological disease, but would represent a 
new era in hypothesis-driven, disease-modifying therapy 
for this poorly served patient population.
It is diﬃ     cult to contemplate how this therapeutic 
approach could have advanced so far in the absence of a 
suitable animal model of the disease. Th  e therapy itself 
involves the interplay of numerous in vivo systems 
impossible to adequately model otherwise. In the case of 
active therapy, the therapeutic response begins with host 
recognition of the Aβ-derived immunogen and subse  quent 
mounting of an antibody-raising immune response. In 
both active and passive therapies, the antibodies likely 
cross the blood-brain barrier (approximately 0.1% of 
serum IgG levels are found in the central nervous system 
[6]), bind to the target and trigger neutralization, clear-
ance and/or removal of pathogenic Aβ species. Acute 
behavioral improvements (due presumably to neutraliz  ing 
the eﬀ  ects of brain interstitial synapto-toxic Aβ oligomers) 
and progressive reductions in Aβ-associated neuro-
pathologies are seen in preclinical rodent and non-human 
models following administration of anti-Aβ antibodies.
Whether these results will translate eﬀ  ectively to the 
complex clinical outcomes awaits the completion of 
human testing. Th   e compelling and extensive replication 
of numerous convergent eﬃ   cacy measures by indepen-
dent investigators and conﬁ  rmation of activity in humans 
continue to place Aβ immunotherapy in the forefront of 
potential new treatments for AD. Th  e use of transgenic 
animal models was essential in this case, and these 
models can be expected to continue to elucidate disease 
mechanisms and thereby enable eﬀ  ective approaches to 
treat, and eventually prevent, the tragic course of AD.
Abbreviations
Aβ = amyloid-beta; AD = Alzheimer’s disease.
Competing interests
The authors are dual employees of Janssen Alzheimer Immunotherapy 
Research and Development, LLC and Neotope Biosciences, a division of Elan 
Pharmaceuticals.
Published: 29 July 2010
References
1.  Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, 
Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter 
R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, 
Yednock T, Games D, Seubert P: Immunization with amyloid-beta 
attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 
1999, 400:173-177.
2.  Wilcock DM, Gharkholonarehe N, Van Nostrand WE, Davis J, Vitek MP, Colton 
CA: Amyloid reduction by amyloid-beta vaccination also reduces mouse 
tau pathology and protects from neuron loss in two mouse models of 
Alzheimer’s disease. J Neurosci 2009, 29:7957-7965.
3.  Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO: 
Neuropathology of human Alzheimer disease after immunization with 
amyloid-beta peptide: a case report. Nat Med 2003, 9:448-452.
4.  Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, 
Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller 
M, Gregg KM, Schenk D, Black R, Grundman M: 11C-PiB PET assessment of 
change in fi  brillar amyloid-beta load in patients with Alzheimer’s disease 
treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, 
ascending-dose study. Lancet Neurol 2010, 9:363-372.
5.  Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, 
Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, 
Lieberburg I, Schenk D, Black R, Grundman M; Bapineuzumab 201 Clinical 
Trial Investigators: A phase 2 multiple ascending dose trial of 
bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 
73:2061-2070.
6.  Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE: Passage of 
amyloid beta protein antibody across the blood-brain barrier in a mouse 
model of Alzheimer’s disease. Peptides 2002, 23:2223-2226.
doi:10.1186/alzrt46
Cite this article as: Games D, Seubert P: The role of animal models in 
advancing amyloid-beta immunotherapy to the clinic. Alzheimer’s Research & 
Therapy 2010, 2:22.
Games and Seubert Alzheimer’s Research & Therapy 2010, 2:22 
http://alzres.com/content/2/4/22
Page 2 of 2